(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.32%.
Annovis Bio's earnings in 2026 is -$40,923,510.On average, 4 Wall Street analysts forecast ANVS's earnings for 2026 to be -$44,881,553, with the lowest ANVS earnings forecast at -$47,535,503, and the highest ANVS earnings forecast at -$41,472,301. On average, 4 Wall Street analysts forecast ANVS's earnings for 2027 to be -$46,648,543, with the lowest ANVS earnings forecast at -$46,177,346, and the highest ANVS earnings forecast at -$46,565,391.
In 2028, ANVS is forecast to generate -$64,141,747 in earnings, with the lowest earnings forecast at -$82,168,512 and the highest earnings forecast at -$44,018,846.